A randomized, double-blind, placebo-controlled study of daily cannabidiol for the treatment of canine osteoarthritis pain.


Journal

Pain
ISSN: 1872-6623
Titre abrégé: Pain
Pays: United States
ID NLM: 7508686

Informations de publication

Date de publication:
01 09 2020
Historique:
received: 18 02 2020
accepted: 16 04 2020
pubmed: 30 4 2020
medline: 15 5 2021
entrez: 30 4 2020
Statut: ppublish

Résumé

Over the last 2 decades, affirmative diagnoses of osteoarthritis (OA) in the United States have tripled due to increasing rates of obesity and an aging population. Hemp-derived cannabidiol (CBD) is the major nontetrahydrocannabinol component of cannabis and has been promoted as a potential treatment for a wide variety of disparate inflammatory conditions. Here, we evaluated CBD for its ability to modulate the production of proinflammatory cytokines in vitro and in murine models of induced inflammation and further validated the ability of a liposomal formulation to increase bioavailability in mice and in humans. Subsequently, the therapeutic potential of both naked and liposomally encapsulated CBD was explored in a 4-week, randomized placebo-controlled, double-blinded study in a spontaneous canine model of OA. In vitro and in mouse models, CBD significantly attenuated the production of proinflammatory cytokines IL-6 and TNF-α while elevating levels of anti-inflammatory IL-10. In the veterinary study, CBD significantly decreased pain and increased mobility in a dose-dependent fashion among animals with an affirmative diagnosis of OA. Liposomal CBD (20 mg/day) was as effective as the highest dose of nonliposomal CBD (50 mg/day) in improving clinical outcomes. Hematocrit, comprehensive metabolic profile, and clinical chemistry indicated no significant detrimental impact of CBD administration over the 4-week analysis period. This study supports the safety and therapeutic potential of hemp-derived CBD for relieving arthritic pain and suggests follow-up investigations in humans are warranted.

Identifiants

pubmed: 32345916
pii: 00006396-202009000-00024
doi: 10.1097/j.pain.0000000000001896
pmc: PMC7584779
mid: NIHMS1586027
doi:

Substances chimiques

Cannabidiol 19GBJ60SN5

Types de publication

Journal Article Randomized Controlled Trial Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2191-2202

Subventions

Organisme : NIAID NIH HHS
ID : P30 AI036211
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA125123
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI127387
Pays : United States
Organisme : NCRR NIH HHS
ID : S10 RR024574
Pays : United States

Informations de copyright

Copyright © 2020 International Association for the Study of Pain.

Références

Expert Opin Drug Saf. 2019 Jul;18(7):581-590
pubmed: 31056959
Toxicol Appl Pharmacol. 2019 Nov 1;382:114713
pubmed: 31437494
J Cell Physiol. 2019 Nov;234(11):21224-21234
pubmed: 31032942
Neuroscience. 1994 Dec;63(4):925-36
pubmed: 7535397
Rheumatology (Oxford). 2012 Nov;51(11):1931-41
pubmed: 22427408
Nat Biotechnol. 2014 Jan;32(1):40-51
pubmed: 24406927
Toxicol Appl Pharmacol. 2019 Apr 1;368:63-71
pubmed: 30796934
Acta Pharmacol Sin. 2010 Dec;31(12):1611-7
pubmed: 21042286
Eur J Pain. 2016 Jul;20(6):936-48
pubmed: 26517407
Trends Pharmacol Sci. 2000 Jul;21(7):244-6
pubmed: 10871891
J Mol Med (Berl). 2009 Nov;87(11):1111-21
pubmed: 19690824
Sci Rep. 2016 Feb 18;6:21703
pubmed: 26887982
Handb Exp Pharmacol. 2005;(168):657-90
pubmed: 16596792
Osteoarthritis Cartilage. 2008 Feb;16(2):137-62
pubmed: 18279766
Am J Public Health. 2018 Feb;108(2):256-258
pubmed: 29267054
Clin Exp Rheumatol. 2017 Sep-Oct;35 Suppl 107(5):53-58
pubmed: 28967360
J Invest Dermatol. 2003 Sep;121(3):502-9
pubmed: 12925208
Best Pract Res Clin Rheumatol. 2006 Feb;20(1):117-29
pubmed: 16483911
Lancet. 2019 Apr 27;393(10182):1745-1759
pubmed: 31034380
Eur J Pharmacol. 2019 Jan 15;843:251-259
pubmed: 30481497
Cochrane Database Syst Rev. 2006 Jan 25;(1):CD004257
pubmed: 16437479
J Rheumatol. 1991 Mar;18(3):436-46
pubmed: 1856812
Pharmacology. 2012;89(3-4):149-55
pubmed: 22414698
Front Vet Sci. 2018 Jul 23;5:165
pubmed: 30083539
Cannabis Cannabinoid Res. 2016 Mar 01;1(1):90-101
pubmed: 28861484
Vet Rec. 2003 Apr 12;152(15):457-60
pubmed: 12723628
Arthritis Rheumatol. 2020 Apr;72(4):557-564
pubmed: 31612614
Med Princ Pract. 2018;27(6):501-507
pubmed: 30173215
MMWR Morb Mortal Wkly Rep. 2017 Mar 10;66(9):246-253
pubmed: 28278145
Inflamm Bowel Dis. 2019 May 4;25(6):1006-1018
pubmed: 31054246
J Pharmacol Exp Ther. 2018 Jun;365(3):652-663
pubmed: 29632236
Front Pharmacol. 2018 Nov 26;9:1365
pubmed: 30534073
Proc Natl Acad Sci U S A. 2000 Aug 15;97(17):9561-6
pubmed: 10920191
Eur J Clin Pharmacol. 2013 Apr;69(4):825-34
pubmed: 23052407
Curr Opin Rheumatol. 2019 May;31(3):271-278
pubmed: 30920973
Pain Res Manag. 2005 Autumn;10 Suppl A:15A-22A
pubmed: 16237477
J Pain. 2002 Jun;3(3):227-33
pubmed: 14622777
Neurology. 2002 Dec 10;59(11):1694-700
pubmed: 12473754
Adv Exp Med Biol. 1991;288:63-70
pubmed: 1659139
Am J Vet Res. 2009 Jun;70(6):727-34
pubmed: 19496661
Arthritis Res Ther. 2019 Jun 13;21(1):146
pubmed: 31196179
Pain. 2017 Dec;158(12):2442-2451
pubmed: 28885454
Chem Biodivers. 2007 Aug;4(8):1770-804
pubmed: 17712819
Cells. 2019 Aug 03;8(8):
pubmed: 31382646
Mini Rev Med Chem. 2019;19(1):3-11
pubmed: 30179131
Autoimmun Rev. 2016 Jun;15(6):513-28
pubmed: 26876387
Aging Clin Exp Res. 2016 Feb;28(1):1-16
pubmed: 26746234
Mol Pharmacol. 2008 Feb;73(2):441-50
pubmed: 17965195
J Clin Pharmacol. 2002 Nov;42(S1):11S-19S
pubmed: 12412831
J Ocul Pharmacol Ther. 2006 Jun;22(3):160-7
pubmed: 16808676
BMJ. 2004 Aug 7;329(7461):324
pubmed: 15286056
J Med Chem. 2006 Feb 9;49(3):1113-7
pubmed: 16451075
Curr Opin Rheumatol. 2018 Mar;30(2):207-214
pubmed: 29206659
J Orthop Res. 2003 Jul;21(4):730-7
pubmed: 12798075
Biomed Environ Mass Spectrom. 1986 Feb;13(2):77-83
pubmed: 2937482
Cannabis Cannabinoid Res. 2018 Dec 26;3(1):282-290
pubmed: 30596146
Nat Rev Rheumatol. 2011 Jan;7(1):33-42
pubmed: 21119608
Clin Sci (Lond). 2017 Oct 25;131(21):2611-2626
pubmed: 28954820
J Small Anim Pract. 1998 Apr;39(4):169-74
pubmed: 9577758
Vet Pathol. 2015 Sep;52(5):803-18
pubmed: 26063173

Auteurs

Chris D Verrico (CD)

Department of Psychiatry.
Department of Pharmacology, Baylor College of Medicine, Houston, TX, United States.

Shonda Wesson (S)

Sunset Animal Hospital, Houston, TX, United States.

Vanaja Konduri (V)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.

Colby J Hofferek (CJ)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.

Jonathan Vazquez-Perez (J)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.

Emek Blair (E)

Valimenta Labs, Fort Collins, CO, United States.

Kenneth Dunner (K)

Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Pedram Salimpour (P)

Boston University School of Medicine, Boston, MA, United States.

William K Decker (WK)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.
Center for Cell and Gene Therapy.
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX, United States.

Matthew M Halpert (MM)

Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.

Articles similaires

Humans Ketamine Propofol Pulmonary Atelectasis Female
Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice

Classifications MeSH